Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.42 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24089980 | 0.77 | ALDH1A1 (0.51) | MAPTSMN1; SMN2MEN1POLBKMT2A | |
| SCHEMBL24110933 | 0.73 | MAPT (0.41) | TP53MAPTLMNAPOLBPDE7A | |
| SCHEMBL23958140 | 0.72 | RAB9A (0.43) | MAPTLMNAPOLBPDE7A | |
| SCHEMBL24110980 | 0.72 | MAPT (0.45) | MAPTPDE7A | |
| SCHEMBL23958271 | 0.71 | MAPT (0.43) | MAPTLMNAMEN1POLBKMT2A | |
| SCHEMBL24111019 | 0.71 | MAPT (0.47) | TP53MAPTLMNAPOLBPDE7A | |
| SCHEMBL24090010 | 0.70 | USP2 (0.52) | MAPTMEN1POLBKMT2APDE7A | |
| SCHEMBL23065087 | 0.70 | PIK3CD (0.47) | KMT2APDE7A | |
| SCHEMBL24090012 | 0.70 | TOP2A (0.60) | MAPTPOLBPDE7A | |
| SCHEMBL1960453 | 0.69 | TP53 (0.70) | TP53MAPTSMN1; SMN2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021215537-A1 | 2-HETEROARYLAMINOQUINAZOLINONE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2021-10-28 | — | — | WO | disclosed |